Screener
Rigel Pharmaceuticals RIGL Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Investing activities | ||
| Maturities of short-term investments | 15,945 | 11,100 |
| Purchases of short-term investments | (23,920) | (21,652) |
| Net cash used in investing activities | (7,975) | (10,552) |
| Financing activities | ||
| Principal payments of term loans | (7,500) | — |
| Net proceeds from issuance of common stock under equity plans | 321 | 484 |
| Repurchases of common stock in connection with employee tax withholding on RSU vesting | (3,740) | — |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's investing cash flow?
- Rigel Pharmaceuticals (RIGL) reported investing cash flow of -$7.98M in Q1 2026.
- How has Rigel Pharmaceuticals's investing cash flow changed year-over-year?
- Rigel Pharmaceuticals's investing cash flow increased by 24.4% year-over-year, from -$10.55M to -$7.98M.
- What is the long-term trend for Rigel Pharmaceuticals's investing cash flow?
- Over 3 years (2021 to 2025), Rigel Pharmaceuticals's investing cash flow has grown at a 2.2% compound annual growth rate (CAGR), from -$86.52M to -$92.37M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Rigel Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude